Eisai Set For Final-Phase Trials Of Second Cancer Drug Indication
This article was originally published in PharmAsia News
Executive Summary
Eisai is on schedule to begin Phase III U.S. trials by the end of March on a second indication for its Ontak (diftitox) lymphoma drug